Moore Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Moore Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,000	Closed	-$1.02M	–	626
2023 Q2	$1.02M	Sell	10,000 -48,301	-83%	-$4.57M	0.02%	307
2023 Q1	$5.3M	Buy	+58,301	New	+$3.42M	0.11%	141
2018 Q4	–	Sell	-15,000	Closed	-$1.23M	–	324
2018 Q3	$1.23M	Buy	+15,000	New	+$1.06M	0.03%	213

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Moore Capital Management's RETA Position: Q3 2023 in Review

Moore Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 10,000 shares — an estimated $1.02M sold.

Moore Capital Management first reported a position in RETA in Q3 2018 and held it in 3 quarters. The position peaked at $5.3M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Moore Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Moore Capital Management sold 10,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.02M.
Moore Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 3 quarters.
Moore Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.3M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.